Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting

INTRODUCTION: Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes (T2D) that has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight versus GLP-1 receptor agonists dulaglutide, exenatide extended-release (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Gæde, Peter, Johansen, Pierre, Tikkanen, Christian Klyver, Pollock, Richard Fulton, Hunt, Barnaby, Malkin, Samuel Joseph Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612343/
https://www.ncbi.nlm.nih.gov/pubmed/31098942
http://dx.doi.org/10.1007/s13300-019-0630-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612343/
https://www.ncbi.nlm.nih.gov/pubmed/31098942
http://dx.doi.org/10.1007/s13300-019-0630-6

Ejemplares similares